Background The human papillomavirus (HPV) vaccine is recommended for adolescent girls in many European countries, however there is huge variation in vaccine uptake.
Methods A mixed methods systematic review to ascertain the level of HPV and HPV vaccine knowledge that exists among European adolescents. Two electronic databases, Ovid Medline and PsychInfo, were searched from origin to September 2014. Meta-analysis was performed for the two primary outcome measures (‘have you heard of HPV?’ and ‘have you heard of the HPV vaccine?’), assessing for the correlation between gender and knowledge. This was supplemented with meta-synthesis for the remaining associations and secondary outcomes.
Results 18 papers were included in the final review. Overall European adolescents had poor understanding of basic HPV and HPV vaccine knowledge. Meta-analysis identified that female adolescents are more likely to have heard of HPV (n=2598/5028 girls versus n=1033/3464 boys; OR 2.73, 95% CI 1.86–3.99) and the HPV vaccine (n=1154/2556 girls versus n=392/2074 boys; OR 5.64, 95% CI 2.43–13.07), compared to males. Age, higher education and a positive vaccination status were also associated with increased awareness. There was limited appreciation of more detailed HPV knowledge and uncertainty existed regarding the level of protection offered by the vaccine and the need for cervical screening post vaccination.
Conclusions The delivery of HPV education to European adolescents needs to be re-evaluated, since at present there appears to be significant deficiencies in their basic knowledge and understanding of the subject. Increasing HPV knowledge will empower adolescents to make informed choices regarding participation with HPV related cancer prevention health strategies.
- HEALTH PROMOTION
Statistics from Altmetric.com
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract that most men and women who are sexually active will acquire at some point in their lives.1 It is the main aetiological factor for cervical cancer with a prevalence of 99.7% in all cases of cervical cancer.2
Following the identification of the role of HPV in the aetiology of cervical cancer, four prophylactic vaccines targeting various high-risk HPV types have been developed. The monovalent vaccine (HPV16), the bivalent vaccine (HPV 16/18), the quadrivalent vaccine (HPV 16/18/6/11)3 and more recently, the nonavalent vaccine (HPV 16/18/6/11/31/33/45/52/58).4 The bivalent and quadrivalent vaccines were licensed for use in 2006/2007 and even over this relatively short period the beneficial effects of the vaccine are already evident; with decreases in the incidence of high-grade cervical abnormalities, the prevalence of vaccine HPV types and the incidence of genital warts.4
The HPV vaccine is widely recommended in many European countries for female adolescents (aged 9–18 years5), however independent of funding discrepancies, the uptake of the vaccine has been variable, ranging from <5–86%.6–8 Reasons for vaccine uptake are multifactorial,9 ,10 however knowledge of HPV and the HPV vaccine have been identified as key predictive factors in increasing uptake.11 To date studies have shown that awareness of HPV across all populations is poor.12 ,13 It was hoped that the health promotion campaigns, which preceded vaccine introduction would result in heightened awareness of HPV, thus far the evidence for this is lacking.14
HPV vaccination is primarily aimed at adolescents and conveying HPV related health information to this group is arguably the greatest challenge for many healthcare professionals.15 In spite of this, it is essential that adolescents fully understand, and are able to critically appraise the information that they are provided, in order for them to make informed choices.16
The aim of this systematic review was to assess the level of HPV and HPV vaccine knowledge that exists amongst European adolescents.
A mixed methods systematic review, exploring qualitative and quantitative data, was conducted to assess our aim. The two main primary outcomes that we assessed were: ‘have you heard of HPV?’ and ‘have you heard of the HPV vaccine?’
We adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for systematic reviews.17 Two electronic databases, Ovid Medline and PyscINFO were searched from establishment to September 2014. These databases were used without any limitations and they were deemed to be the most relevant databases for this research question. Searches were conducted using 11 combinations of the keywords ‘HPV’, ‘Papillomavirus’, ‘Human papilloma virus’, ‘Health knowledge’ ‘Attitudes’, ‘Practice’, ‘Patient education’, ‘Vaccine/vaccination’ and ‘Primary prevention’ limited to English language and human participants.
All studies reporting data specifically on HPV and/or HPV vaccine knowledge in European adolescents were included. The upper age limit, for this review was set at a mean age of 20 years. This was because in some studies, which had been conducted in European secondary schools, the upper age limit reached 20 years.18–21 Only studies, which were conducted in a member country of the European Union, were included. We excluded studies in which the main focus was vaccine uptake, acceptability or attitudes. Studies providing insufficient information, for example letters/abstracts only, were also excluded.
Two researchers (HP, ELM) independently reviewed the full texts for quality and suitability. The Critical Appraisal Skills Programme tool was used to review the qualitative studies22 and a quality checklist was developed, following the principles identified by Petticrew and Roberts23 and using the Centre for Evidence-Based Management tool,24 for the quantitative survey studies. Any discrepancies were discussed until a consensus was reached.
Study features and outcomes were assembled in a tabular form, and formal meta-analysis was performed using RevMan.25 A random-effects model (using the Mantel-Haenszel (MH) method) was used as the I2 statistic showed heterogeneity of >50%. The effect estimate was expressed as a pooled OR with 95% CI and was represented graphically by forest plots. Statistical heterogeneity was examined using the χ2 test and a p value of <0.05 was suggestive of heterogeneity. Clinical heterogeneity was examined by assessing the participants, intervention used, study quality and outcome measures. The meta-analysis was supplemented with meta-synthesis for the secondary outcome measures.
The literature search revealed 905 suitable studies following the removal of duplicates (see online supplementary file 1). The full texts of 29 articles that had met the initial inclusion criteria were reviewed and 11 of these studies were excluded. Reasons for exclusion included age of participants, studies not assessing HPV or HPV vaccine knowledge, study assessing the effect of intervention and adequate information not supplied. Studies that had published results in more than one publication were amalgamated resulting in 4 qualitative and 14 quantitative studies to be included in the final review. Publication dates of the studies ranged from 2008 to 2013. Sample size ranged from 217 to 1769 for the quantitative and from 10 to 87 for the qualitative studies. Most of the included studies had been conducted in a Western European country (UK, Italy, Sweden, the Netherlands, Portugal, Germany), with only two from Eastern Europe, both from Hungary. Study characteristics are summarised in web tables 1 and 2.
The majority of studies were considered to be of moderate to good quality (see online supplementary file 2). The response rate was greater than 70% in all but two studies.20 ,26 However many of the studies predominately used convenience sampling and therefore the representativeness of the data may be questioned.
Awareness of HPV
‘Have you heard of HPV?’
Twelve of the quantitative studies specifically assessed for this outcome.18–21 ,27–34 Awareness of HPV varied between the studies with the lowest level existing among a cohort of Swedish adolescents, mean age 16 years, where only 5% had ever heard of HPV.18 The highest level of awareness of HPV was noted in Italian adolescents, mean age 16 years, where 92% had heard of HPV.21 Awareness of HPV in Italian female adolescents has increased over time,19 ,21 ,28 a similar trend has been noted for male and female adolescents in the Netherlands31 ,34 and Sweden.18 ,30
Factors found to be associated with greater HPV awareness included:
Vaccinated girls were more likely to have heard of HPV than unvaccinated girls35 (77%, n=683 vs 8.5%, n=76; p=0.01727)in two UK studies, however adolescent boys appeared to have an equal level of awareness as unvaccinated girls in a German study.26
Higher education in general and, in particular, students studying a medical or health sciences related subject were found to correlate with greater awareness compared with non-health science subjects.31 ,33 ,34
Knowledge was found to positively increase with age20 and in one Italian study, it was noted that each 1 year increment in age resulted in 14% increased knowledge.28 In addition, a Hungarian study demonstrated that adolescents attending secondary school had better knowledge than those attending primary school (40%, n=463 vs 25%, n=152; p≤0.001).32
Only one German study revealed a correlation with sexual experience, showing that students who had previous sexual experience had superior awareness of HPV than those who had never had sex (OR 1.53, 95% CI 1.01 to 2.12).20
Gender was found to be the greatest and most consistent predictive factor for having heard of HPV. Meta-analysis of eight quantitative studies showed that adolescent girls are more likely to have heard of HPV compared with the boys, (n=2598/5028 girls versus n=1033/3464 boys; OR 2.73, 95% CI 1.86–3.99) (figure 1).19–21 ,30–34
Awareness of HPV vaccine
‘Have you heard of the HPV vaccine?’
Five quantitative studies assessed for this outcome.18 ,20 ,21 ,30 ,32 Highest levels of vaccine awareness were again found in Italian adolescents, 94.5% and 71.3% of girls and boys, respectively, in the group who had heard of HPV had also heard of the HPV vaccine.21 This is a substantial improvement on the findings by Di Giuseppe et al28 who in 2007, found that in Italy only 42% of those that had heard of cervical cancer, identified HPV vaccination was a preventative measure and only 15% knew that the vaccine was available in Italy. Knowledge of the HPV vaccine among Swedish adolescents was found to be extremely low, with awareness reaching a maximum of 9.2% in girls in one study30 and in another the overall awareness was only 1.1% with no significant difference noted in gender.18 Lower levels of vaccine awareness corresponded to low awareness of HPV in these cohorts.
Meta-analysis of the four studies that analysed gender differences in awareness, found that girls were more likely to have heard of the HPV vaccine (n= 1154/2556 girls versus n= 392/2074 boys; OR 5.64, 95% CI 2.43–13.07) (figure 2)20 ,21 ,30 ,32 and interestingly many adolescent boys felt that it did not even concern them.19
Mode of transmission
On the whole adolescents had a sound understanding of the fact that HPV is a sexually transmitted disease.18 ,19 ,21 ,26–28 ,30–32 ,34 ,36 ,37 First-year medical students in a UK based study, had the greatest level of knowledge regarding mode of transmission37 and the lowest levels were found among groups in which not many had heard of HPV in the first instance.18 ,30 Very few recognised that HPV can be transmitted through genital skin-to-skin contact or non-penetrative intercourse.27 ,28 ,32 Other routes of transmission, which had been erroneously suggested included, the airborne route where students had applied the knowledge that they held for other viruses, such as the influenza virus, to HPV.38 In addition some mentioned blood transfusions,33 the use of public toilets and poor intimate hygiene.21
Link to cervical cancer and genital warts
The correlation between high-risk HPV and cervical cancer was poorly understood, with a group of 12–13-year-old girls in the UK believing that HPV and cervical cancer were the same.38 In two UK based studies, despite the majority of the participants having heard of HPV, only 50% or less were aware of its link to cervical cancer27 ,37 and one of these studies had been conducted in 1st-year medical students.37
Compared with boys, girls in general20 ,21 ,30 ,32 ,34 and vaccinated girls26 were found to have greater knowledge of the relationship between HPV and cervical cancer. Misconceptions existed regarding the hereditary nature of cervical cancer, 76% of medical faculty students incorrectly stated hereditary cause as a risk factor.31
Level of protection offered by the vaccine
Adolescents appreciated that the HPV vaccine provided protection against cervical cancer but uncertainty existed on the exact level of protection offered.27 ,36 ,37 Only a few knew that it was still possible to get cervical cancer after receiving the vaccine27 and that the vaccine only offers protection against some of the high-risk HPV subtypes.37 One group of girls thought that the vaccine would not stop them from getting cervical cancer but that it would stop them dying from it.36 A minority mentioned that it may also protect against ‘STDs’19 and genital warts.21 Others falsely believed that the HPV vaccine also provided protection against HIV/AIDs and viral hepatitis.21 The two Swedish studies revealed that adolescents felt their intention to use condoms would decrease after receiving the HPV vaccine and that other adolescents would feel the same,18 ,30 however Italian adolescents acknowledged the need to use condoms during sexual activity following vaccination.21
Need for cervical screening in the future
Four27 ,36 ,38 ,39 UK based studies found that the need for cervical screening following vaccination was not clear. Some thought that cervical screening was being provided as a ‘backup’ for those who were still concerned after being vaccinated rather than it being mandatory for all.39 Vaccinated female medical students in the UK and Italian adolescents appeared to be more aware of the requirement for cervical screening.21 ,37
Our review reveals that the level of HPV and HPV vaccine knowledge among European adolescents remains suboptimal. These results reinforce the findings of another review of European adolescents which found that of all the sexually transmitted diseases the lowest level of awareness existed for HPV.40 Recent systematic reviews concluded that increased HPV knowledge does result in increased vaccine uptake and acceptability.11 ,12 When vaccine recipients and their parents are provided with balanced information, they have improved knowledge and risk perception, which results in increased vaccine uptake.41
In this review we attempted to identify factors, which may be associated with greater HPV knowledge. The following factors were explored looking for any correlations.
An emergent theme from our review was that female gender correlated with increased knowledge. Studies from across Europe showed that female adolescents had more knowledge than boys, a trend which is also replicated in the adult population.13 This is likely to be reflective of the fact that HPV is primarily thought of as a women's health problem and that the majority of countries presently only recommend the HPV vaccine for women. However HPV is responsible for malignancies in men too, including cancers of the anus, penis, oral cavity and oropharynx42 and furthermore men share an equal burden for HPV related genital warts.43 Currently HPV vaccination for adolescent boys is only recommend by a few, including America, Canada, Australia and Austria. Furthermore, the UK's Joint Committee on Vaccination and Immunisation has recently recommended that men who have sex with men (aged 16–40 years) should also be offered the HPV vaccine.44 The cost-effectiveness of the vaccine has been debated as the rational against vaccinating adolescent boys.44 Moreover it has been argued that boys will receive a degree of protection from the herd immunity effect of vaccinated girls. However HPV vaccination is only part of the solution, abstaining from high-risk behaviour is equally important. Parents feel that by including boys in HPV education and in the vaccination campaign we can reinforce their responsibility in sexual health45 and avoid girls feeling stigmatised by being the sole target.46 The challenge will be to develop educational materials which are equally relevant to both genders.
Introduction of the HPV vaccine into national immunisation programmes and funding
The timing of HPV vaccine introduction across Europe has varied and integration into national immunisation programmes and/or funding are not universal. The results of this review do not consistently support the concept that the availability of a fully state-funded HPV immunisation programme at the time of the study resulted in increased awareness. The highest levels of HPV awareness were noted in Italian adolescents, in a study conducted in 2009, 1–2 years after the HPV vaccine was introduced into the Italian national vaccination schedule,47 and the lowest levels were seen in Sweden in 2007, 3 years prior to implementation of the HPV vaccine.48 However, studies from Hungary32 and the Netherlands31 ,34 showed a greater level of HPV awareness than Germany,20 despite the former studies being conducted prior to the implementation of a free national HPV vaccination programme in their respective countries5 and the German study taking place 4 years post ‘free of cost’ vaccine introduction in Germany.49 These findings imply that much more complex factors are involved in acquiring knowledge and that the introduction of national HPV vaccination alone is not predictive.
Organisation of a vaccination programme, school based versus primary care/private
It has been proposed that countries, such as the UK and Australia, which have school based vaccination programmes have achieved higher vaccination coverage rates.50 However the studies within our review showed that the UK, which operates a school based vaccination programme, has a vaccine coverage rate of 86%7 but Portugal, where the HPV vaccine is administered in primary care and health centres,49 also had a comparable coverage rate of 84%.6 The organisation of HPV vaccine administration did not correlate with level of knowledge in this review, however knowledge was related to vaccine uptake: Italy, UK and Portugal had the highest levels of vaccine uptake and also the greatest amount of knowledge.
Delivery of information
Vaccine introduction in many European countries was preceded by health promotion campaigns, including school based presentations.51 ,52 The successfulness of these campaigns may be questioned, as overall HPV knowledge in this cohort remains insufficient. This raises the possibility that information may have been inappropriately targeted in some countries. McCusker et al, who specifically compared HPV knowledge, pre and post a HPV health promotion campaign in the UK, found that the campaign did not over time add much in terms of HPV knowledge.37
Adolescents in this review described their main sources of information as media, schools and the internet.28 ,30 ,32 ,37 They felt that although written information was useful, it needed to be more user-friendly and complemented with nurse-led small group discussions.38 Currently a recommendation cannot be made on the most effective way of communicating HPV related information, as no one method has been found to be superior.50 However it is apparent that adolescents are requesting more information than that which is presently available.28 ,30 ,32 ,35 ,36 In addition the challenge will be maintaining knowledge over time.53 When delayed posteducation follow-up has been conducted, even after only 1 month, the initially noted benefit is diminished.54 This suggests that there is a need for continued educational reinforcement as opposed to a single intervention session. This is particularly important with regards to cervical screening post vaccination.
Strengths and limitations
There have been previous systematic reviews assessing HPV knowledge in various different populations12–14 ,55 ,56 but this is the most up-to-date review that focuses on the primary target group for the HPV vaccine: adolescents.
Our review was a comprehensive mixed methods review, using this approach provides more accurate data, which is likely to have greater impact.57
However it was limited by the scope of the primary studies. Five of the survey studies had not validated their questionnaires and there were considerable variations in the way specific acceptance of HPV knowledge were assessed, for example prompted versus open questions. In our review an upper age limit of 20 years was adopted, this meant that some of the included studies had been conducted at university level and although the average age did not exceed 20 years, this is a vastly different population. Lastly, the study populations were all heterogeneous and therefore difficult to truly compare.
Current evidence suggests that European adolescents have limited understanding of basic factual HPV knowledge. HPV plays a pivotal role in the present and future of preventative cancer strategies for both genders. Methods of delivering HPV information to this complex group need to be re-evaluated to promote increased awareness and empower them to make informed choices regarding future preventative health behaviours.
Current evidence suggests that European adolescents lack basic factual human papillomavirus (HPV) knowledge and that female gender is consistently associated with greater HPV awareness.
HPV is becoming more prevalent and is responsible for malignancies in both genders, however the risk of acquiring it can be reduced.
Previous evidence has shown that increased HPV awareness does result in increased HPV vaccine uptake.
In order to increase participation with HPV related cancer prevention health strategies, methods of delivering HPV related information need to be re-evaluated.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Handling editor Jackie A Cassell
Contributors HP, YBJ, SMS and ELM were involved in planning the review and contributed equally to manuscript preparation and review. HP conducted the literature search and data extraction, performed the meta synthesis of the qualitative data and wrote the initial draft of the manuscript. YBJ performed the statistical analysis for the meta analysis. HP and ELM contributed to quality assessment of the studies. All authors approved the final report.
Competing interests SMS has been awarded the following grant; 2015—North Staffordshire Medical Institute, Pump Priming Award. Mothers and Daughters: Exploring knowledge about and attitudes towards cervical screening and HPV vaccination.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All authors had full access to all the data in the study.